tirzepatide lipolysis Vasso's Corner: Tirzepatide, a new era for dual-treatment for type-2 diabetes and obesity Tirzepatide and other GLP1RA as

Understanding why nausea occurs is the first step in managing it effectively

Within the cohort, 4.5% of participants in the semaglutide group and 0.8% of participants in the placebo group discontinued treatment due to gastrointestinal events

Practical management strategies include: Dietary modifications : Eating smaller portions, choosing low-fat options, and avoiding trigger foods can minimise nausea and digestive discomfort Hydration : Maintaining adequate fluid intake helps manage constipation and supports overall wellbeing Injection technique : Rotating injection sites (abdomen, thigh, or upper arm) reduces local reactions Timing : Injections can be given at any time of day, with or without food

As a result, many people on GLP-1 therapy naturally eat much less than before